ESMC earnings analysis
What we found in ESMC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Escalon Medical Corp. reported a decline in consolidated net revenue of approximately $601,000 or 6.3% to $8,875,000 for the nine months ended March 31, 2026, mainly due to reduced sales in key segments including Sonomed and Trek products. Additionally, cash on hand increased significantly to $3,343,000 following a successful asset sale, despite ongoing operational losses and rising expenses in marketing and administration.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Revenue Decline
- Consolidated net revenue decreased $601,000 or 6.3% to $8,875,000 for the nine months ended March 31, 2026.
- Increased Cash Reserves
- Cash on hand rose to $3,343,000 from approximately $546,000 as of June 30, 2025, primarily from a software asset sale.
- R&D Expense Reduction
- R&D expenses decreased $377,000 or 18.4% during the nine-month period compared to the previous year.
- Higher Operating Expenses
- Marketing and administrative expenses increased by $349,000 or 10.2% for the nine months ended March 31, 2026.
- Improved Working Capital
- Working capital increased to $4,034,000 from $1,927,000 at June 30, 2025.
- Debt to Capital Ratio Improvement
- Debt to total capital improved to 19.6% from 21.5% as of June 30, 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sales Decline in Key Segments
- Sales from Sonomed products fell by $310,000 and Trek products by $305,000 contributing significantly to revenue decrease.
- Ongoing Operating Losses
- The company reported a net operating loss of $523,000 during the nine months ended March 31, 2026.
- Impact of Tariffs
- Recent tariff measures may increase costs and impact profitability, particularly with increased import costs.
What they reported.
What the company itself reported, taken out of the document.
- Segment
- Products revenue decline: $6,859,000 compared to $8,015,000 last year (15.5%)
- Segment
- Service revenue: $1,658,000 compared to $1,354,000 last year (22.4%)
What they said about what is next.
Management indicates continued monitoring of operational costs; no specific numeric guidance provided.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 17, 2026
- Escalon Medical Corp. reported a 4.4% increase in consolidated net revenue of $6.267 million for the six months ended December 31, 2025, driven primarily by Sonomed product sales. However, operating cash flow showed a…
- 10-Q · November 14, 2025
- Escalon Medical Corp. reported a decline in consolidated revenue of 3.8% to $2,675,000 for the three months ended September 30, 2025, compared to the same quarter last year, largely due to decreased sales in Sonomed and…
- 10-K · September 29, 2025
- Escalon Medical Corp. reported modest growth in revenue, with total revenue increasing by 0.5% to approximately $12.05 million for the fiscal year ending June 30, 2025. The company achieved net income of approximately…
- 10-Q · May 14, 2025
- Escalon Medical Corp. reported an 11.4% year-over-year increase in revenue to $9,476,000 for the nine months ended March 31, 2025, driven primarily by higher sales in ophthalmological products. In the latest quarter,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ESMC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever